drugset / Trial / NCT06741969
Nipocalimab in Moderate to Severe Sjogren's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD).
Timeline
- Start
- 2024-12-04
- Primary completion
- 2028-01-01
- Completion
- 2029-05-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nipocalimab | Monoclonal antibody | — | Subcutaneous |